Abstract:Lung cancer is the leading cause of cancer-related death worldwide, with a poor prognosis. Despite aggressive treatment, progression-free survival (PFS) and overall survival are limited. Recently, various kinds of immune checkpoint inhibitors (ICIs) have emerged for several cancers, targeting PD1, PDL1, and CTLA-4. ICIs have made a significant breakthrough in cancer and revolutionized the management of cancer including lung cancer. However, there are a lot of controversies regarding which group of patients is most suitable to be treated with ICIs in terms of monotherapy, combination, and predictive biomarkers. We reviewed various kinds of studies, such as meta-analysis, randomized control trials, multi-center cohort studies, and case-control studies from PubMed written in English from the last five years. ICIs have significant benefits in the overall survival compared with traditional chemotherapy. Patients with a higher level of PDL1 expression and high tumor mutational burden (TMB) have a higher response rate, and those with EGFR-/ALK- were better than those with EGFR+/ALK+. The patient who responded to immunotherapy completely can still maintain the efficacy after two years of treatment. Neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer resulted in a 45% major pathology response (MPR) and 40% downstaging. Combined therapy (ICIs + chemotherapy) was better than chemotherapy alone, irrespective of PD-L1 expression. A combination of ICIs such as CTLA-4 and PD-1/PD-L1 improved PFS as well. Radiochemotherapy ahead of ICIs is promising as well. However, ICIs combined with EGFR/ALK-TKI (tyrosine kinase inhibitor) are not suggested for the time being. PDL1 expression, TMB, and EGFR/ALK mutations are promising predictive biomarkers. Gut microbiota, galectin-3, and intensity of CD8 cell infiltration are other potential predictive biomarkers. These are very important in the future management of lung cancers as they can prevent unnecessary toxicities and cost of treatment.

P18.01 Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors

Treatment Efficacy of HER2-mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors: a Multicenter Retrospective Study

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer

Recent Advances and Challenges of Immune Checkpoint Inhibitors in Immunotherapy of Non-Small Cell Lung Cancer

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Efficacy of Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer Patients with Different Genes Mutation

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

EP08.01-093 ICI in Combination with Chemotherapy or Anti-angiogenic Agents As Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.

Efficacy and Safety of Immune Checkpoint Inhibitors in Post-Tki NSCLC Patients Harboring EGFR Mutations

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma